Summary

Sell, $33.33 target: the InP shortage is real, but the price already pays for it

InitiationBy Penmark Team
AXTISell$33.33-14%
Page 1 of 24
Equity research | Initiation of coverage | United States
Compound-semiconductor substrates | Coverage: Initiated | Published 10 Nov 2026, 09:00 ET
Penmark Team | research@penmarkresearch.com
AXT Inc (Nasdaq: AXTI)

Sell, $33.33 target: the InP shortage is real, but the price already pays for it

Rating
Initiation
Sell
12-month target
$33.33
Price, 6 Nov
$38.88
Price return*
−14.3%
Total return
−14.3%
Bull case
$61.85
Bear case
$11.98
*Rating = price return to target, excl. dividends: Buy above +10%, Hold −10% to +10%, Sell below −10%. Total return is for information (no dividend).

We initiate at Sell with a $33.33 target, 14.3% below the $38.88 close. AXT makes the indium phosphide (InP) wafers under AI optical lasers, and demand exceeds supply. Our FY27E EPS of $2.63 matches consensus, but the price pays for a 54% mid-cycle gross margin where we model 40%.

  • Mid-cycle gross margin is 40%, not the 54% the price implies. History runs 12.7% to 43.0%; worth $3.41 a share (Debate 1).
  • Pricing falls from 1.05x to 0.73x by FY31E as JX, Sumitomo and PRC capacity arrive; worth $3.25 a share (Debate 2).
  • The Tongmei round costs $1.12 a share if no listing follows, as investors can redeem at cost plus 8% a year (Debate 3).

What the market is missing. FY26E revenue of $237.9m is in line with $239.4m consensus. The price solves to a 53.8% mid-cycle margin or a 9.5% cost of equity; we use 40% and 11.9%.

Catalysts. 27 Nov 2026 expiry of China’s US-specific gallium and germanium suspension; Feb 2027 4Q26 results (guided ~$90m); mid-2027 InP capacity doubling.

Valuation and target. DCF base $31.05, mid-cycle P/E cross-check $27.93. Bear $10.70 (30%), base $31.05 (50%), bull $55.27 (20%) weight to $29.79, rolled to $33.33.

Risks. Upside: capacity beating plan (+$2.27 a share), Tongmei listing (+$1.12). A 1pt lower cost of equity gives $35.84 (−7.8%, Hold).

Exhibit 1: EPS reaches $2.56 in FY27E; the stock trades on 14.8x FY27E non-GAAP EPS
Year end 31 Dec, $mFY24AFY25AFY26EFY27EFY28E
Revenue99.488.3237.9509.9717.0
Growth y/yn/a(11.1%)169.4%114.3%40.6%
EBITDA(5.8)(12.9)91.7261.3360.3
Margin(5.9%)(14.6%)38.5%51.2%50.2%
Net income to AXT(11.6)(21.3)72.5169.2223.2
EPS, GAAP ($)(0.27)(0.49)1.132.563.38
EPS growthn/an/an/a125.7%32.0%
FCF incl. prepayments(17.9)(18.8)n/a84.7114.3
At $38.88FY24AFY25AFY26EFY27EFY28E
P/E, non-GAAPn/mn/m32.4x14.8x11.3x
P/E, GAAPn/mn/m34.3x15.2x11.5x
EV/EBITDAn/mn/m19.8x7.0x5.0x
EV/sales18.3x20.6x7.6x3.6x2.5x
FCF yield(0.7%)(0.7%)n/a3.3%4.4%
Dividend yield0.0%0.0%0.0%0.0%0.0%
P/B, total equityn/m7.7x1.6x1.4x1.2x
P/E at our targetn/mn/m27.8x12.7x9.7x

Source: Company filings (A); Penmark Research model (E). EV before Tongmei round. FCF incl. customer prepayments; FY26E n/a (3Q26 cash flow not filed). Shaded = estimates.

Base value is $31.05 and the weighted target $33.33: upside is $22.97 against $26.90 of downside

Exhibit 3: Bull $61.85, base $34.74, bear $11.98 in 12 months; weighted target is 14.3% below the price
$0$50$100$150Jan-26Jul-26Jan-27Jul-27ActualEstimatesPrice $38.88Bull $61.85 (+59%)Base $34.74 (−11%)Bear $11.98 (−69%)Target $33.33 (−14%)

Source: Yahoo Finance closes; Penmark Research model. Scenario targets are model values rolled forward 12 months at the 11.9% cost of equity.

Scenarios and price target basis
Bull$61.85+59.1%20% prob.

InP stays short into FY29, capacity 2.2x in FY27, US permits granted, Tongmei listed; mid-cycle margin 46%.

Base$34.74−10.6%50% prob.

Capacity 2.0x in FY27, utilisation 97% to 82%, price index 1.05 to 0.73, margin 60% to 40% mid-cycle.

Bear$11.98−69.2%30% prob.

Export permits squeezed, FY27 utilisation 75%, price index 0.55 by FY30, mid-cycle margin 29.8%, 60% no listing.

Price target (weighted)$33.33−14.3% = Sell
Upside to downside0.9x+$22.97 / −$26.90
Exhibit 4: Revenue rises 8.1x from FY25A to $717m by FY28E as InP scales
Income statement, $mFY24AFY25AFY26EFY27EFY28E
Revenue99.488.3237.9509.9717.0
Gross profit23.811.2128.5305.9401.5
EBITDA(5.8)(12.9)91.7261.3360.3
EBIT(14.8)(22.0)81.3243.9331.5
Net financial items4.10.417.328.429.7
Tax(1.1)(1.7)(13.9)(40.9)(54.2)
Net income, GAAP(11.6)(21.3)72.5169.2223.2
Net inc., non-GAAPn/an/a76.5173.7228.0
Exhibit 5: Capex of $160m in FY27E leaves $85m of free cash flow
Cash flow, $mFY24AFY25AFY26EFY27EFY28E
Net income, consol.(11.8)(23.2)84.8231.5307.1
D&A and SBC12.112.414.321.833.5
Working capital, other(12.4)(2.0)n/a(8.7)(76.3)
Operating cash flow(12.1)(12.8)n/a244.7264.3
Capex(5.8)(6.0)n/a(160.0)(150.0)
FCF incl. prepay.(17.9)(18.8)n/a84.7114.3
Customer prepay.n/an/an/a20.0(15.0)
FCF excl. prepay.n/an/an/a64.7129.3
Exhibit 6: Net cash reaches $1,510m by FY28E, mostly Tongmei round money
Balance sheet, $mFY24AFY25AFY26EFY27EFY28E
Cash, investments231281,3841,4681,583
Receivables26274877108
Inventory8582104112156
PP&E, net160162217359480
Total assets3394341,8072,0712,381
PRC bank loans4763727272
Net cash(24)661,3111,3961,510
Total equity2553351,5721,8082,120
Exhibit 7: EPS reaches $2.63 (non-GAAP) in FY27E on 66.1m shares
Per share and KPIsFY24AFY25AFY26EFY27EFY28E
Diluted shares, m43.243.962.866.166.1
EPS, non-GAAP ($)n/a(0.42)1.202.633.45
EPS, GAAP ($)(0.27)(0.49)1.132.563.38
Dividend/share ($)0.000.000.000.000.00
FCF/share ($)(0.41)(0.43)n/a1.281.73
Equity/share ($)5.917.6223.7927.3632.08
InP revenue ($m)n/an/a169.5433.2633.6
InP utilisationn/an/an/a97%95%

Source: Company filings (A); Penmark Research model (E). $m unless stated; FY ends 31 December. Cash includes restricted cash and investments; total equity includes non-controlling and redeemable interests. FY26E cash flow n/a: 3Q26 cash flow not filed at the model date. Bold = totals and thesis lines.

Returns turn positive in FY26E and we are within 2% of consensus on EPS; the debate is margin, not volume

Exhibit 8: Margins swing from −14.6% to +50.2% EBITDA by FY28E
Growth, margins (%)FY24AFY25AFY26EFY27EFY28E
Growth y/y
Salesn/a−11.1%169.4%114.3%40.6%
EBITDAn/an/an/a185.1%37.9%
EBITn/an/an/a200.0%35.9%
EPS, GAAPn/an/an/a125.7%32.0%
DPSn/an/an/an/an/a
Margins
Gross margin24.0%12.7%54.0%60.0%56.0%
EBITDA margin−5.9%−14.6%38.5%51.2%50.2%
EBIT margin−14.9%−24.9%34.2%47.8%46.2%
FCF margin−18.0%−21.3%n/a16.6%15.9%
Capex / sales5.8%6.8%n/a31.4%20.9%
Exhibit 9: Net cash and 12.7x FY27E P/E at our target; returns turn positive in FY26E
Ratios and valuationFY24AFY25AFY26EFY27EFY28E
Returns and leverage
ROEn/an/a8.9%13.7%15.6%
ROAn/a−6.0%7.6%11.9%13.8%
ROCEn/an/a8.0%13.8%16.3%
Net debt / equityn/a−19.6%−83.4%−77.2%−71.2%
Net debt / EBITDAn/mn/m−14.3x−5.3x−4.2x
Valuation at $38.88
P/E, non-GAAPn/mn/m32.4x14.8x11.3x
EV/EBITDAn/mn/m19.8x7.0x5.0x
P/B, total equityn/m7.7x1.6x1.4x1.2x
FCF yield(0.7%)(0.7%)n/a3.3%4.4%
Dividend yield0.0%0.0%0.0%0.0%0.0%
P/E at our targetn/mn/m27.8x12.7x9.7x

Source: Penmark Research model; company filings. Ratios derived from model statements: ROE, ROA, ROCE on average total equity, assets and equity plus bank debt; net debt negative = net cash. Multiples at the 6 Nov 2026 price of $38.88 except the last row (at our $33.33 target). P/E non-GAAP excludes SBC; FY27E EV/EBITDA uses EV before the Tongmei round.

Exhibit 10: We are 1.7% above consensus on FY26E EPS and 0.9% below on FY27E
$m; EPS $4Q26EFY26EFY27E
Revenue ($m)
Penmark estimate90.0237.9509.9
Consensus91.5239.4516.7
Prior-year period23.088.3237.9
Diff. vs consensus(1.7%)(0.6%)(1.3%)
Growth y/y (Penmark)290.6%169.4%114.3%
Adjusted EPS ($)
Penmark estimate0.581.202.63
Consensus0.571.182.65
Prior-year period(0.05)(0.42)1.20
Diff. vs consensus1.8%1.7%(0.9%)
Growth y/y (Penmark)n/mn/m118.9%

Source: Penmark Research model; consensus LSEG via Yahoo Finance, Nov 2026; 4Q25 and FY25 from company filings. 4Q26E guided ~$90m revenue and $0.57–0.59 non-GAAP EPS.

Exhibit 11: EPS climbs to $3.45 by FY28E; FY26E and FY27E sit within 2% of consensus
Consensus−$1$0$1$2$3$4FY25AFY26EFY27EFY28EActualEstimates−$0.42$1.20$2.63$3.45

Source: Company filings (A); Penmark Research model (E); consensus LSEG via Yahoo Finance, Nov 2026 (amber tick).

Where we differVolume and EPS are in line with consensus. We model a 60% FY27E gross margin, matching the CFO’s “above 60%”, but non-controlling interests take $62.4m (27%) of FY27E consolidated net income after the Tongmei round, so EPS lands level with consensus.

Next 12 months hinge on permits and capacity; AXTI is not cheap on history, and only fairly priced against peers

Exhibit 12: AXTI trades 10% below peers on forward P/E despite more than twice their growth
6 Nov 2026AXTIPeersDiff.
Valuation
Fwd P/E, at price14.8x16.5x−10.3%
Fwd P/E, at target12.7x16.5x−23.0%
Mid-cycle P/E (anchor)15.6xn/an/a
Growth, returns and risk
Rev. growth, 3Y fcst101%43%+58pp
Gross margin, TTM44.0%38.2%+5.8pp
Beta, 5Y2.011.65+0.36
Debt / equity0.080.31−0.23

Source: Penmark Research model; peers Coherent, Lumentum, Photronics median (S&P Global Market Intelligence data, 6 Nov 2026). AXTI FY27E non-GAAP P/E; gross margin is trailing twelve months. Cost-of-equity beta 1.41 is the peer median relevered (Exhibit 70). Difference in % for multiples, absolute or pp for ratios.

Exhibit 13: Four dated catalysts: permits in November, results in February
  • 18 NovAPEC Shenzhen, 18–19 Nov; AI dialogue due by end-Nov. A first US-bound InP permit: +$0.07 a share (25%); we assume none.
  • 27 NovChina’s US-specific gallium and germanium ban suspension expires. A squeeze on permits takes FY27 utilisation from 97% to 75% (−$0.52).
  • Feb 20274Q26 results: we expect $90.0m revenue and $0.58 non-GAAP EPS; consensus $91.5m and $0.57.
  • Mid-2027InP capacity update: base case already doubles capacity; 2.2x adds $2.27 a share (40%); a miss costs $0.12.

Source: Company filings and calls; Penmark Research model catalyst re-runs.

Exhibit 14: Upside risks to the Sell: $3.79 a share if the first three land
  • Capacity beats the 2.0x plan. InP capacity of 2.2x instead of 2.0x in FY27 lifts value. Probability 40%; +$2.27/share.
  • Tongmei listing completes. No-IPO odds fall from 40% to 0%, removing the 8% redemption floor. Probability 60%; +$1.12/share.
  • Shortage runs to FY29. Utilisation 5 to 10 points higher in FY28 to FY29. Probability 35%; +$0.40/share.
  • Supply wave cuts prices harder. A further 0.10 off the price index from FY29 supports the Sell. Probability 55%; −$2.60/share.
The Sell is invalidated if the cost of equity falls 1pt (target $35.84, −7.8%, Hold) or the share price falls below $37.04, (return to our target passes −10%).

Source: Penmark Research model; value = base-case re-run less base value, probability as set in the model.

Exhibit 15: AXT gross margin averaged 28.3% since FY09 and peaked at 43.0%; the price needs 53.8%
10%20%30%40%50%60%FY09AFY12AFY15AFY18AFY21AFY24AMean 28%; bands ±1σ, ±2σ13%Our mid-cycle 40%Price-implied 53.8%

Source: Company filings FY09–FY25; Penmark Research model. Forward P/E history is not meaningful: AXT lost money in FY23–FY25.

Exhibit 16: Forward P/E rises with gross margin; AXTI at 14.8x sits near the line
5x10x15x20x25x30x20%30%40%50%60%Forward P/EGross margin, TTMAXTICOHRLITEPLABMTSIENTGAAOISWKSSumitomo Elec.R² 0.53, n=9

Source: Yahoo Finance (peer data as of 10 Nov 2026); Penmark Research (AXTI at the 6 Nov price of $38.88 and FY27E EPS). Includes uncovered Sumitomo Electric.

PART 1 · SUMMARY · 3 THE THESIS IN CHARTS

The stock follows gross margin, and the price already pays for a 54% mid-cycle level

Exhibit 17: Non-GAAP gross margin tracks the share price at 0.93 correlation over eight quarters
Quarter-end price ($)Non-GAAP gross margin (right)$0$20$40$60$800%10%20%30%40%50%60%4Q241Q252Q253Q254Q251Q262Q263Q26

Source: Yahoo Finance quarter-end closes; company releases and calls (non-GAAP gross margin). 4Q24 to 3Q26; the 6 Nov price of $38.88 is outside the series.

Exhibit 18: InP revenue rose 6.8x in three quarters to $54.3m, 74% of 3Q26 sales
$0m$20m$40m$60m4Q251Q262Q263Q26$8.0m$13.6m$30.7m$54.3m

Source: Company earnings calls, CFO prepared remarks; 4Q25 stated approximately.

Exhibit 19: Price index falls from 1.05 to 0.73 by FY31E; utilisation eases from 97% to 82%
Price and mix index (4Q26 = 100)Utilisation, %708090100110FY27EFY28EFY29EFY30EFY31E7382

Source: Penmark Research model, Revenue build, base case. Index is relative to the 4Q26 price and mix.

Exhibit 20: The price needs a 53.8% mid-cycle margin or a 9.5% cost of equity; we use 40.0% and 11.9%
Market view / consensusPenmarkMid-cycle gross marginCost of equity40.053.89.511.9

Source: Penmark Research model, Market Check, in % (price-implied solves at $38.88, base case).

Exhibit 21: Primary and cross-check values sit below the $38.88 price; only the bull case is above it
DCF, bear to bullMid-cycle P/E, thesisrangeCost of equity ±1pt,weighted$0$20$40$60$10.70$55.27$26.80$32.80$27.79$32.32Price $38.88Target $33.33

Source: Penmark Research model (Valuation, Thesis, Market Check); bear to bull range of the DCF, thesis range of the P/E cross-check, and cost of equity of 10.9% to 12.9%.

Exhibit 22: Three debates explain nearly all of the $7.83 gap between the $38.88 price and our $31.05 base value
$0$10$20$30$40PriceMid-cyclemarginPriceindexTongmeifloorOtherBasevalue$38.88−$3.41−$3.25−$1.12−$0.05$31.05

Source: Penmark Research model, Market Check debate re-runs (each driver set to the market view, base case).

PART 1 · SUMMARY · 4 KEY DEBATES

Three debates decide the stock, and the price sits on the market side of all three

The market capitalises shortage-era margins and prices as permanent and expects Tongmei to list. We model a supply response from FY28 and a 40% chance that the listing fails.

Exhibit 23: We are on the other side of the market on three debates worth $7.78 a share in total
DebateMarket viewPenmark viewEvidenceWhat would change our viewResolves
1. How high is mid-cycle gross margin?Shortage pricing becomes the norm: 46% (bull case); the price implies 53.8%.40%: a supply wave from FY28 pulls margin back; value $31.05 against $34.46.AXT ran 12.7% to 43.0% from FY09 to FY25; InP is now ~74% of sales; JX, Sumitomo and Yunnan Germanium add capacity.Gross margin still above 50% in FY29 results.FY29 to FY30 results
2. How far does InP pricing fall?Price index holds at 0.88 from FY31 (bull case).0.73 by FY31E; value $31.05 against $34.29.JX plans ~7x to 10x capacity by ~FY30; Sumitomo 3.1x FY24 level by FY28; AXT and Sumitomo are ~80% of supply today.Lead times stay above nine months and allocation continues through FY28.JX and Sumitomo ramps, FY28
3. Does Tongmei list within three years?Listing is certain: 0% chance of no IPO.40% chance of no qualified IPO; redemption at cost plus 8% a year costs $1.12 a share.STAR listing pending 2021 to 2026, then withdrawn; investor backs overseas listing (8-K, 28 Oct 2026).A filed Hong Kong prospectus before the late 2029 deadline.Late 2029

Source: Company filings and calls; Penmark Research model (Market Check). Value per share: base-case DCF with one driver at the market view.

Exhibit 24: On all three debates the market view is worth $1.12 to $3.41 a share more than ours
Value at market viewValue at our view1. Mid-cycle margin2. InP price index3. Tongmei listing$31.05$34.46$31.05$34.29$31.05$32.17

Source: Penmark Research model, Market Check: full re-runs with one driver at the market view.

How the debates map to the thesis

Each debate has one chapter. Debate 1 (margin, $3.41) is chapter 1; debate 2 (price, $3.25) is chapter 2; debate 3 (Tongmei, $1.12) is chapter 3. Section 9 links drivers to debates.

Why the market is wrong

The price capitalises shortage margins as permanent. At $38.88 the market needs a 53.8% mid-cycle gross margin; AXT has not earned more than 43.0% in any fiscal year FY09 to FY25.

Exhibit 25: The next 12 months are event-driven; margin and pricing debates resolve in FY28 to FY30 and the Tongmei listing by late 2029
27 Nov 2026Gallium and germaniumsuspension expiresFeb 20274Q26 resultsMid-2027InP capacity doublingupdateFY28JX and Sumitomo rampsLate 2029Tongmei IPO deadlineFY29 to FY30FY29 results: mid-cyclemargin

Source: Company filings and calls; Penmark Research. February 2027 results date is an estimate, not company-confirmed.

PART 2 · THE BUSINESS · 5 THE BUSINESS (1 OF 3): THE STORY

Quarterly sales leapt from $28m to $73m in a year, and the price assumes the shortage never ends

AXT grows the crystals that sit under lasers and radio chips, all in China. Demand for one, indium phosphide, has outrun supply.

39 yearsIncorporated in California, Dec 1986
35%Revenue from top five customers, 3Q26
$88.3mRevenue, FY25A
74%InP share of 3Q26 revenue
$2.57bnMarket value at $38.88

The scene

On 29 October 2026, AXT told investors that its order backlog had passed $500m, up from a little over $100m three months earlier. That is more than five years of FY25 sales ($88.3m). Every customer was on allocation, management said, with lead times past nine months. AXT is a Fremont, California company, listed since 1998.

What it actually does

Chips are built on a thin crystal disc called a wafer. AXT grows indium phosphide (InP) crystals, used in optical lasers, and gallium arsenide (GaAs), used in radio and sensor chips, then slices and polishes them. It does not design chips. About a third of sales are raw materials such as gallium.

How the money comes in

Customers pay per wafer, and the price rises when wafers are scarce. In 3Q26, InP brought in $54.3m of $73.4m revenue (74%), GaAs $9.1m (12%), raw materials $9.7m (13%) and germanium $0.3m. Of each dollar of FY27E revenue we model, 48 cents is operating profit and 17 cents is free cash flow after capex.

Where the story turns

In February 2025 China put InP substrates on its export-control list, so every InP wafer needs a Chinese permit. InP revenue then rose from $8.0m to $54.3m in three quarters and non-GAAP gross margin from 21.5% to 56.1%. On 28 October 2026 AXT agreed to invest $400m in its subsidiary Tongmei alongside up to $545m from outsiders, leaving AXT with 73.4%.

Why it works, and why it might not

Management says only one other supplier is at parity in 6-inch InP. The loop breaks if rivals add capacity: JX plans roughly 7x to 10x and Sumitomo 3.1x by FY28 to FY30 (debate 2, section 4).

53.8%Gross margin the price needs for ever
AXT has not topped a 43.0% gross margin in any fiscal year since FY09; the $38.88 price implies 53.8%.Source: Company filings FY09 to FY25; Penmark Research model, Market Check. We assume 40.0%; the gap is worth $3.41 a share.
1 · WHO COMES
35%Top five customers, 3Q26 revenue.
2 · WHAT THEY BUY
74%InP share of 3Q26 revenue.
3 · WHAT THEY PAY
$43.5mLumentum prepayment, 3Q26.
4 · WHAT AXT KEEPS
56.1cGross profit per $1, 3Q26.

Exhibit 26: One customer, start to finish. Source: Company call and release, 29 Oct 2026; Penmark Research model.

PART 2 · THE BUSINESS · 5 THE BUSINESS (2 OF 3): HOW THE COMPANY MAKES MONEY

InP now brings in 74% of revenue and 56 cents of every dollar becomes gross profit

Exhibit 27: Of each $1 of 3Q26 revenue, 56 cents was gross profit and 39 cents operating profit
InP wafers$54.3mGaAs wafers$9.1mRaw materials, Ge, other$10.0mRevenue $73.4m$73.4mCost of revenue$32.3mGross profit$41.1mR&D, SG&A (GAAP)$12.7mOperating profit$28.4m

Source: Company 3Q26 results release (8-K, 29 Oct 2026), GAAP; product split from CFO remarks. 3Q26 (quarter to 30 Sep 2026).

Exhibit 28: Five operating numbers moved sharply in one quarter
$54.3m+77% on 2Q26InP revenue, 3Q26>$500mfrom >$100m in 2Q26Order backlog56.1%+11.1pp on 2Q26Non-GAAP gross margin35%+5pp on 2Q26Top five customers$0.41from $0.19 in 2Q26Non-GAAP EPS

Source: Company releases and calls, 29 Oct 2026 and 30 Jul 2026; Signals KPI series.

What it sells, and why customers buy

InP wafers are what the market is short of. AXT and Sumitomo supply about 80% of InP; all customers are on allocation.

How it is priced and paid for

Customers pay per wafer. Lumentum prepaid $43.5m in 3Q26; AXT is pulling back from long-term agreements to keep pricing flexible.

Cash versus profit

We model FY27E operating cash flow of $244.7m against $160.0m of capex: free cash flow is $84.7m.

Exhibit 29: Quarterly revenue has risen 2.6x in a year to $73.4m, after four quarters near $20m to $28m
$0m$20m$40m$60m$80m4Q241Q252Q253Q254Q251Q262Q263Q26$25m$19m$18m$28m$23m$27m$48m$73m

Source: Company filings and releases (A), 4Q24 to 3Q26; quarter ends 31 December to 30 September.

Exhibit 30: InP added $46.3m of the $50.4m revenue growth since 4Q25
$m4Q251Q262Q263Q263Q26 share
InP wafers8.013.630.754.374%
GaAs wafers7.05.46.69.112%
Germanium, raw materials, other8.07.910.310.014%
Total revenue23.026.947.673.4100%
Non-GAAP gross margin21.5%29.9%45.0%56.1%

Source: Company calls, CFO prepared remarks, 4Q25 to 3Q26; Signals KPI series. 4Q25 InP and GaAs are stated approximately; other = total less InP and GaAs.

PART 2 · THE BUSINESS · 5 THE BUSINESS (3 OF 3): DRIVERS AND CONCENTRATION

Revenue is capacity times utilisation times price, and price is the input we expect to fall

Exhibit 31: FY27E revenue of $509.9m is InP capacity times utilisation times price; those three inputs are the forecast
Average capacity$425.3m a yr; exit 2.0xUtilisation97% (FY28E 95%)Price and mix index1.05x (FY31E 0.73x)InP wafers$433.2m, +156%GaAs and germanium$35.9m, +15%Raw materials, other$40.8m, +10%Revenue FY27E$509.9m, +114%

Source: Penmark Research model, Revenue build, base case. Capacity in $m of quarterly revenue at 4Q26 prices; index relative to 4Q26.

Exhibit 32: InP grows to 88% of FY28E revenue of $717m in our base case
InPGaAs and germaniumRaw materials, other$0m$200m$400m$600m$800mFY26EFY27EFY28E$238m$510m$717m

Source: Penmark Research model, Revenue build (E). Revenue by product, $m.

Exhibit 33: 65% of 2Q26 revenue shipped to China; top five customers were 35% by 3Q26
ChinaEuropeTaiwanJapanOther2Q26 revenue, $47.6m65%19%5%3%8%

Source: Company 10-Q 2Q26 (revenue by destination, via Signals); top-five share from Signals KPI series. Other includes North America $0.2m.

Exhibit 34: Base-case gross margin falls from 60% in FY27E to 40% by FY31E; bear case reaches 15% in FY30E
10203040506070FY27EFY28EFY29EFY30EFY31EBull 46Base 40Bear 30

Source: Penmark Research model, Assumptions (gross margin by scenario, %); FY31E bear = historical median 29.8%. FY09 to FY25 range 12.7% to 43.0%.

Fixed and variable cost to deliver

Operating costs are mostly fixed, so margin follows price. Operating expenses rise only from $47m in FY26E to $62m in FY27E while revenue grows 114%; gross margin does the work (60% FY27E, 40% from FY31E).

Concentration

Every wafer is made in China and sold by permit. InP, GaAs and germanium all need Chinese export permits; none for US-bound InP has been approved. The top five customers were 29% of 2025 revenue and 35% in 3Q26.

PART 2 · THE BUSINESS · 6 AND 7 THE MARKET AND COMPETITIVE POSITION

Two suppliers hold about 80% of InP today, and three rivals are adding 3x to 10x capacity

Exhibit 35: AXT sits at the two cheapest steps of the chain, where the shortage sets the price
Gallium, indium,germaniumChinese refiners13% of AXT salesCrystals and wafersAXT, Sumitomo, JX87% of AXT salesEpitaxy and lasersCoherent, LumentumCustomersOptical modulesTransceiver makersCustomers’ customersData centresAI networksEnd demandAXT: 13% raw materials, 87% wafers

Source: Company 10-K FY25 and 3Q26 call; Penmark Research. Chain simplified to the steps AXT sells into.

Exhibit 36: AXT and Sumitomo hold about 80% of InP while rivals plan 3x to 10x more capacity
~80%InP supply held by AXT andSumitomo$11.8bnCoherent vendor purchasecommitments$2.35bnLumentum purchase obligations3x to 10xRival InP capacity additionsplanned

Source: Company 10-K FY25; Coherent and Lumentum FY26 10-Ks; management 3Q26 call; Penmark Research model.

Exhibit 37: Rivals plan to add 3x to 10x InP capacity by FY28 to FY30
AXT, FY26 exit vs FY25exitSumitomo, FY28 vs FY24Yunnan Germanium,plannedJX, ~FY30 vs now2x4x6x8x10x2.8x3.0x3.0x3.2x2.9x3.1x7.0x10.0x

Source: Management 3Q26 call; JX release 16 Jun 2026; Nikkei; Reuters (as logged in the Penmark model). Bases differ by company; markers are mid-points.

Exhibit 38: Five advantages, none proven beyond FY28
AdvantageEvidenceLasting?
Low defect densityBarrier at 8-inch GaAs; premium for low-EPD InP (10-K FY25)Medium
Own raw materialsGallium and germanium made in-house; 13% of salesMedium
Recent capacityOnly supplier to add significant facilities recently (10-K)Fades by FY28
6-inch InPOne other supplier at parity (CEO, 3Q26 call)Medium
China cost positionAll output made in the PRC under export permitsCuts both ways

Source: Company 10-K FY25; 3Q26 call; Penmark Research assessment.

Where the margin sits and who threatens it

AXT and Sumitomo supply about 80% of InP today, so price is set by scarcity, not cost. New supply arrives from JX (7x to 10x over four years), Sumitomo (3.1x by FY28) and Yunnan Germanium, while AXT itself doubles capacity again in FY27. Demand is unusually concentrated: Coherent has $11.8bn of vendor purchase commitments and Lumentum $2.35bn of purchase obligations (FY26 10-Ks), so double ordering is a cycle risk as well as a demand signal.

Exhibit 39: Our 40% mid-cycle margin matches industry history; the price needs 53.8%, above every year AXT has reported
AXT median FY09 to FY25Photronics, Entegris median FY16 to FY25Our mid-cycle assumptionAXT peak, FY11AXT 3Q26 (non-GAAP)Price-implied mid-cycle29.840.140.043.056.153.8

Source: Company filings; Signals key metrics (Photronics FYE Oct, Entegris FYE Dec); Penmark Research model, Normalisation and Market Check. Gross margin in %.

What this means for valueWe take the supply response at face value: a 0.10 lower price index from FY29 costs $2.60 a share (55% probability) and is the largest single risk in the model.
PART 2 · THE BUSINESS · 8 MANAGEMENT, GOVERNANCE AND CAPITAL ALLOCATION

Management has beaten its last two revenue guides by 11% or more, but insiders sold $29m in June to August

Exhibit 40: The board grew from four to six in 2026 with two independent directors; the CEO is the one non-independent member
Director / officerSinceRole
Morris S. Young1989Chairman, CEO; not independent
Jesse Chen1998Lead independent director
David C. Chang2000Independent director
Leonard J. LeBlanc2025Independent director
Tracy LiuJun 2026Independent; ACM Research audit chair
Jia-Bin DuhJul 2026Independent; ex-Microsoft China
Gary L. Fischer2014CFO, Secretary (not a director)

Source: 2026 proxy statement (DEF 14A); company 8-K filings of 22 Jun and 22 Jul 2026. Board expanded to five on 17 Jun and six on 16 Jul 2026.

Management record

Management beat its last two revenue guides by 11% and 40%. In January 2026 it cut 4Q25 guidance on fewer export permits and then landed inside the cut range.

Pay and independence

Half of the annual equity award is tied to a financial metric. Awards vest over four years; say-on-pay passed on 4 Jun 2026 with 97.4% of votes cast (18.26m for, 0.41m against, 0.08m abstaining). Five of six directors are independent; the four directors in the 2026 proxy are aged 68 to 85.

Exhibit 41: Four insiders sold about $29m of stock in June to August 2026 at $87 to $115
Morris S. Young, CEOJesse Chen, lead directorDavid C. Chang, directorLeonard J. LeBlanc,director$22.3m$5.3m$0.9m$0.6m

Source: SEC Form 4 filings via Signals, 1 Jun to 19 Aug 2026; proceeds = shares x price per filing. Sales only; CEO figure includes option exercises.

Exhibit 42: Diluted shares rose 53% from 43.2m to 66.1m; no buyback and no dividend
0m20m40m60m80mFY24AFY25AFY26EFY27EActualEstimates43.2m43.9m62.8m66.1m

Source: Company filings (A); Penmark Research model (E). FY26E is the weighted average; 4Q26E run-rate 66.1m.

Exhibit 43: Reported revenue beat guidance by 11% to 40% in the last two quarters
GuidedGuideReportedResult
Revenue, 4Q25$22.5m to $23.5m$23.0mIn range
Revenue, 2Q26~$34m$47.6m+40%
Non-GAAP EPS, 2Q26$0.06 to $0.08$0.19Above
Revenue, 3Q26~$66m$73.4m+11%
Non-GAAP EPS, 3Q26$0.30 to $0.32$0.41Above

Source: Company releases and calls; Penmark Research model, Guidance. Guides given 8 Jan, 30 Apr and 30 Jul 2026; ranges or approximate figures.

Capital allocation

AXT spends on capacity and funds it with Tongmei equity, not buybacks. We model $160m of capex in FY27E and $150m in FY28E against $25m in 4Q26E; the Tongmei round adds up to $545m of outside capital and $400m from AXT. Governance does not hold back the rating; the concern is the $545m of outside capital with an 8% redemption floor (debate 3, $1.12 a share).

PART 3 · THE THESIS · 9 WHAT MOVES THE STOCK (1 OF 2)

The stock trades on InP margins and optics sentiment, and the market has priced both above our value

Three drivers pass at least two of three tests: gross margin and InP pricing, capacity and backlog, and optics sentiment. The stock trades on the InP supply story and on its peers, not on the market.

Exhibit 44: Three drivers pass two tests; the market reaction exceeds what our model supports
DriverTestsMarket reactionModel valueDebateNext number
1. Gross margin and InP pricingEvents, Q&A+21% to +29% on three beats; −9.6% on the fourth$3.41 a share1, 24Q26 GM: 64.5% (ours)
2. InP capacity and backlogQ&A, eventsBacklog >$500m; 39 of 91 questions$2.27 a share2Mid-2027: 2.0x capacity
3. Optics and AI sentimentFactors, eventsR² 0.44; −54% in a month$2.53 a share1Coherent and Lumentum prints

Source: Penmark Research model (Market Check, Sensitivities), Yahoo Finance, Signals call transcripts. Model value = difference between value at the market view and at our view, base case; driver 3 = cost of equity 1pt lower.

Exhibit 45: The stock moved 17% on average (absolute) the day after results, against 2% for the sector
SOXXAXTIFeb 25May 25Jul 25Oct 25Feb 26Apr 26Jul 26Oct 26−31.0−3.13.03.5−7.7−1.20.48.61.024.70.921.20.128.7−9.6−8.2

Source: Yahoo Finance daily closes, next-session reaction in % to the last eight results (20 Feb 2025 to 29 Oct 2026); Penmark Research calculation.

Exhibit 46: Optical peers explain 44% of daily moves; the market explains 17%
S&P 500SOXX (chip index)Coherent + LumentumSOXX + Coherent +Lumentum0.170.280.440.44

Source: Yahoo Finance daily returns, 1 Oct 2025 to 6 Nov 2026; OLS R-squared of AXTI on each factor, Penmark Research calculation.

Exhibit 47: Capacity and demand took 39 of 91 analyst questions; Tongmei took 2
Capacity, overcapacity,supplyDemand, backlog,agreementsGross margin and pricingExport permits, ChinaTongmei, capital, listingOther topics22171212226

Source: Signals call transcripts, 4Q25 to 3Q26; 91 analyst-question paragraphs coded by topic, Penmark Research.

Dropped candidates

The market and Tongmei do not move the stock. The S&P 500 explains 17% of daily moves and the chip index 28%. Tongmei and capital raising drew 2 of 91 questions, though it is worth $1.12 a share to us (debate 3). Export permits drew 12 questions but have no measured event-day reaction, so they stay in the risk register.

Exhibit 48: Four numbers frame the drivers: 0.93 margin-price correlation, 0.44 R-squared to optics peers
0.93Gross margin to price correlation,8 quarters0.44Daily R-squared vs Coherent andLumentum39 of 91Analyst questions on capacity anddemand−9.6%Stock move after 3Q26 results

Source: Yahoo Finance, Signals call transcripts and company releases; Penmark Research calculations.

PART 3 · THE THESIS · 9 WHAT MOVES THE STOCK (2 OF 2)

Each driver is worth $2 to $4 a share to us; none supports the price on its own

DRIVER 1InP gross margin sets the share price, and the market capitalises its peak.

What the market does. Non-GAAP gross margin rose from 21.5% (4Q25) to 56.1% (3Q26) while the price rose from $16.35 to $77.41; the correlation is 0.93 over eight quarters. At $38.88 the price implies a 53.8% mid-cycle margin.

What our model says. A 40.0% mid-cycle margin is worth $31.05 a share; the market view (46%) is worth $34.46. The gap is $3.41, or 8.8% of the price.

Debate and next number. Debates 1 and 2 (section 4). Next: 4Q26 results in February 2027 (date unconfirmed). We expect revenue of $90.0m and gross margin of 64.5%; consensus revenue is $91.5m. The last four results moved the stock −9.6% to +28.7%.

DRIVER 2The pace of InP capacity growth, not demand, limits revenue.

What the market does. Backlog above $500m and capacity at 2.75x to 3.0x FY25 exit. Capacity and demand were 39 of 91 analyst questions; management had no worry about overcapacity for about two years.

What our model says. Doubling capacity in FY27 is already in our base case; beating it (2.0x to 2.2x) adds $2.27 a share (40% probability), and a 5pt lower FY27 utilisation under the Coherent clause costs $0.12.

Debate and next number. Debate 2 (section 4). Next: mid-2027 capacity update; we model $141.8m of quarterly InP capacity exiting FY27 against $70.9m exiting FY26.

DRIVER 3AXT trades as a levered bet on optics and AI sentiment.

What the market does. Daily R-squared against Coherent and Lumentum is 0.44 (correlation 0.53 and 0.52). From the 6 Oct close of $84.06 to $38.88 on 6 Nov the stock fell 53.7%, a month that included sector weakness, the 28 Oct Tongmei round and the 29 Oct 3Q26 results (−9.6% next session); SOXX fell 30.5% in the same month.

What our model says. The price implies a 9.5% cost of equity against our 11.9%. A one-point lower cost of equity lifts the weighted value to $32.32 and the target to $35.84 (−7.8%, Hold), the only robustness test that changes the rating.

Debate and next number. Debate 1 (section 4). Next: Coherent and Lumentum quarterly results (dates unconfirmed); beta has no model estimate, so we do not forecast the reaction.

Exhibit 49: Each confirmed driver is worth $2.27 to $3.41 a share in our model
Mid-cycle gross margin (debate 1)Capacity 2.0x to 2.2x (debate 2)Optics sentiment: cost of equity 1pt lower$3.41$2.27$2.53

Source: Penmark Research model, Market Check and Sensitivities (base case; optics driver is the change in probability-weighted value, $29.79 to $32.32).

PART 3 · THE THESIS · 10 CHAPTER 1: MARGIN

Chapter 1: the price needs a 54% mid-cycle gross margin; we model 40%

THESIS CHAPTER 1 · RESTS ON SECTION 9 DRIVER 1Mid-cycle gross margin is 40%, not the 54% the price implies.

What the market believes

The price of $38.88 needs a 53.8% mid-cycle gross margin; our bull case uses 46%. The price therefore requires peak margins to persist through the cycle.

The evidence

  • Reported: AXT earned 12.7% to 43.0% across FY09 to FY25, median 29.8%.
  • Industry: Photronics and Entegris ran 20.3% to 46.4%, median 40.1%.
  • Management: the CFO expects FY27 gross margin above 60%, and the CEO sees no overcapacity for about two years.

What it is worth

We take the shortage to FY28 (60%, 56%) and fade to 40% from FY31E. At the market view of 46% the base value is $34.46; the difference is $3.41 a share. Using the historical median in every case gives $23.91.

Signposts

  • FY29 results: margin still above 50% would break our view.
  • 3Q27 to 4Q27 prints: margin below 60% confirms fade; above 64.5% breaks our view.
Exhibit 50: Value per share is $31.05 at 40% margin; 45% with a 0.10 higher price index reaches only $36.41
$26.40$27.64$28.88$30.12$31.36$28.20$29.62$31.05$32.47$33.89$30.01$31.61$33.21$34.81$36.41Mid-cycle gross margin35.0%37.5%40.0%42.5%45.0%FY31E price index shiftIndex −0.10Index +0.00Index +0.10

Source: Penmark Research model, Sensitivities (full model re-runs at the 6 Nov 2026 price and inputs, base case).

Exhibit 51: Quarterly non-GAAP gross margin reached 56.1% in 3Q26, above our 40% mid-cycle level and the 43.0% FY09 to FY25 peak
01020304050604Q241Q252Q253Q254Q251Q262Q263Q2656Our mid-cycle 40%Price-implied 53.8%

Source: Company releases and calls (A), 4Q24 to 3Q26; Penmark Research model (reference lines).

What this means for valueThe price is $7.83 a share above our $31.05 base value. Debate 1 explains $3.41 of it; at the historical median margin in every case the weighted value falls to $23.91 and the target to $26.75.
PART 3 · THE THESIS · 11 CHAPTER 2: PRICING

Chapter 2: InP pricing falls from FY29, worth $3.25 a share against the market view

THESIS CHAPTER 2 · RESTS ON SECTION 9 DRIVER 1InP pricing falls from FY29 as three rivals add capacity.

What the market believes

The bull case holds the price index at 0.88 from FY31. The price pays for a durable shortage.

The evidence

  • Company release: JX plans roughly 7x to 10x InP capacity over four years (16 Jun 2026).
  • Press: Sumitomo targets 3.1x its FY24 level by FY28 (Nikkei); Yunnan Germanium plans 450k wafers a year (Reuters).
  • Filings: Coherent has $11.8bn of vendor purchase commitments and Lumentum $2.35bn of obligations: double ordering can unwind.

What it is worth

Our index falls to 0.73 by FY31E (market view 0.88): $3.25 a share. A further 0.10 off the index from FY29 costs $2.60 (55% probability); a double-ordering unwind costs $0.42.

Signposts

  • FY28: JX and Sumitomo ramp dates and wafer lead times.
  • Lead times shortening from 9+ months signals the turn.
Exhibit 52: InP revenue stalls at $600m to $650m from FY28E as the price index falls to 0.73
InP revenue, $mPrice and mix index (4Q26 = 100) (right)$0m$200m$400m$600m$800m708090100110FY26EFY27EFY28EFY29EFY30EFY31E

Source: Penmark Research model, Revenue build, base case (E). Index relative to 4Q26 price and mix.

Exhibit 53: The supply wave is the largest swing: $2.60 a share down against $2.27 up
Bear 2: price index −0.10Bull 1: capacity 2.2xBull 5: Tongmei listsBear 5: no-IPO odds 60%Bear 1: permit squeezeBear 4: double orderingBase $31.05−$2.60+$2.27+$1.12−$0.57−$0.52−$0.42

Source: Penmark Research model, Sensitivities (catalyst re-runs, base case, $ a share).

What this means for valuePricing carries the Sell: even if capacity beats the 2.0x plan and adds $2.27, a 0.10 lower price index removes $2.60. The 55% probability on the price fall is an analyst judgement, not a measured frequency.
PART 3 · THE THESIS · 12 CHAPTER 3: TONGMEI

Chapter 3: the Tongmei round dilutes AXT to 73.4% and carries an 8% redemption floor

THESIS CHAPTER 3 · RESTS ON DEBATE 3 (TONGMEI IS A DROPPED STOCK DRIVER IN SECTION 9)Tongmei’s funding round costs AXT $1.12 a share, and the market ignores it.

What the market believes

The round is a clean positive: $400m from AXT and up to $545m from outside investors build $947.6m of Tongmei net cash, and a listing follows.

The evidence

  • 8-K, 28 Oct 2026: AXT subscribes $400m for 342,998,797 shares and ends with 73.4% of Tongmei.
  • 10-K FY25: the STAR Market IPO process ran from 2021 and was then withdrawn.
  • Terms: investors can redeem at cost plus 8% a year if no qualified IPO within three years.

What it is worth

We put 40% on no qualified IPO in three years (bear 60%, bull 20%). The redemption floor costs $1.12 a share against a certain listing, and new investors hold 16.2% of Tongmei equity; with existing minorities, non-controlling interests take 27% of FY27E net income.

Signposts

  • Late 2029: IPO deadline; an earlier Hong Kong filing lifts value.
  • 3Q26 10-Q: deposits and cash by entity.
Exhibit 54: From $1,523m of enterprise value to $2,052m of AXT equity: new investors take $470m
$0m$500m$1000m$1500m$2000m$2500mDCF EVTongmei netcashDeposits, JVInvestorsOther holdersParent cashRoll-forwardEquity$1523m+$948m−$85m−$470m−$239m+$351m+$23m$2052m

Source: Penmark Research model, Valuation (equity bridge, DCF, base case, $m); 66.1m shares gives $31.05. Deposits $57.5m (30 Sep estimate); JV minorities $27.2m; "Other holders" = existing Tongmei minorities.

Exhibit 55: Weighted value is $29.79 against a $38.88 price; bear carries 30% probability
$0$20$40$60$10.70$31.05$55.27Bear30%Base50%Bull20%Weighted $29.79Price $38.88

Source: Penmark Research model, Scenarios (value at price date, $ a share). Bear assumes 60% no-IPO probability, bull 20%.

What this means for valueDebate 3 is the smallest in value ($1.12) but binary: the bear case puts 60% on the floor binding. The round lowers AXT ownership from 85.5% to 73.4%.
PART 4 · THE NUMBERS · 13 TRACK RECORD AND QUALITY OF REPORTED NUMBERS

AXT lost money in three of five years; GAAP and non-GAAP EPS differ by only $0.07

Exhibit 56: Revenue halved from $141.1m in FY22 to $75.8m in FY23 and gross margin fell to 12.7% by FY25
Revenue, $mGross margin, % (right)$0m$50m$100m$150m10152025303540FY21AFY22AFY23AFY24AFY25A

Source: Company 10-K filings FY21 to FY25 via Signals; gross margin in %.

Exhibit 57: Free cash flow was negative in all five years, cumulatively −$113.9m
−$40m−$30m−$20m−$10m$0mFY21AFY22AFY23AFY24AFY25A−$33m−$37m−$7m−$18m−$19m

Source: Company 10-K filings via Signals; operating cash flow less capital expenditure.

Exhibit 58: Five years of reported results: the FY26E to FY28E profit step is unprecedented
$m unless statedFY21AFY22AFY23AFY24AFY25A
Revenue137.4141.175.899.488.3
Revenue growthn/a2.7%−46.3%31.1%−11.1%
Gross margin34.5%36.9%17.6%24.0%12.7%
Operating income (GAAP)12.912.6−21.6−14.8−22.0
Diluted EPS, GAAP ($)0.340.37−0.42−0.27−0.49
Stock-based compensation4.54.03.53.13.3
Capital expenditure29.628.510.55.86.0

Source: Company 10-K filings FY21 to FY25 via Signals; Penmark Research. FY22 growth from FY21 revenue of $137.4m.

Adjusted versus reported

The gap between GAAP and non-GAAP EPS is small: $0.07 in FY25A and $0.07 in FY27E. Only stock-based compensation is excluded ($3.3m in FY25A, $4.5m in FY27E). The DCF treats it as a cash cost.

Profit to cash

Cash conversion has not been tested in an upcycle. FY27E operating cash flow is $244.7m against $231.5m consolidated net income, after $28.7m of working-capital build; capex takes $160.0m.

What flatters the numbers

Customer prepayments and minorities need watching. Customer deposits are estimated at $57.5m at 30 Sep 2026 (the 10-Q was not filed at the model date); we deduct them in the equity bridge. Minority interests take $62.4m of FY27E consolidated net income, so net income to AXT is $169.2m of $231.5m.

Inventory

Inventory was $103.7m at 30 Sep 2026, 117% of FY25 revenue; the FY27E build to $111.8m is modest.

Exhibit 59: AXT lost money at the operating line in 8 of 17 years, with a median margin of 4.1%
8 of 17Years with negative operatingmargin, FY09 to FY25−28.5%Worst operating margin, FY2326.4%Best operating margin, FY114.1%Median operating margin

Source: Company 10-K filings FY09 to FY25 via Signals; Penmark Research model, Normalisation (operating income divided by revenue).

PART 4 · THE NUMBERS · 14 FORECASTS

Our forecasts match consensus on revenue and EPS and differ on how long the margin lasts

Exhibit 60: Revenue stalls near $700m from FY28E to FY30E while gross margin falls from 60% to 41%, so EBITDA peaks in FY28E at $360.3m
Revenue, $mGross margin, % (right)$0m$200m$400m$600m$800m102030405060FY24AFY25AFY26EFY27EFY28EFY29EFY30EFY31EActualEstimates

Source: Company filings (A); Penmark Research model (E), Financials. Revenue in $m; gross margin in %.

Exhibit 61: We forecast EPS peaking at $3.45 in FY28E, then falling 32% by FY30E as prices normalise
$m unless statedFY26EFY27EFY28EFY29EFY30EFY31E
Revenue237.9509.9717.0719.7693.7750.6
Gross margin54.0%60.0%56.0%46.0%41.0%40.0%
EBITDA91.7261.3360.3295.5251.6267.2
Non-GAAP EPS ($)1.202.633.452.782.352.49
Capexn/a160.0150.0110.080.075.1
FCF incl. prepaymentsn/a84.7114.3141.8151.0149.8

Source: Penmark Research model, Financials (base case); FY26E free cash flow not modelled because 9M FY26 cash flow was not filed. Estimates shaded.

Exhibit 62: All six 4Q26 guidance items are inside management’s range
4Q26EGuidePenmarkConsensus
Revenue ($m)88.2 to 91.890.091.5
Gross margin60% to 65%64.5%n/a
Operating expenses, GAAP ($m)13.7 to 14.314.0n/a
EPS, GAAP ($)0.56 to 0.580.56n/a
EPS, non-GAAP ($)0.57 to 0.590.580.57
Diluted shares (m)66.0 to 66.266.1n/a

Source: Company 3Q26 call (29 Oct 2026); Penmark Research model; consensus LSEG via Yahoo Finance.

Volume, price and cost

Capacity doubles in FY27E; revenue growth then slows from 40.6% in FY28E to 0.4% in FY29E. Utilisation eases from 97% to 82% and the price index from 1.05x to 0.73x.

Fixed and variable cost

Operating costs rise from $62m in FY27E to $80m in FY31E; capex falls from $160m to $75m once capacity is built.

Against consensus

Revenue and EPS are within 2% of consensus. Our 60% FY27E gross margin matches the CFO’s “above 60%”; minorities absorb its effect on EPS.

PART 4 · THE NUMBERS · 15 VALUATION (1 OF 2)

Both valuation methods land at $28 to $31 a share, below the $38.88 price

Exhibit 63: The DCF carries $1,523m of enterprise value; terminal value is 50.5% of it
$m4Q26EFY27EFY28EFY29EFY30EFY31E
EBIT44.1243.9331.5257.1207.4220.1
Less tax on EBIT−5.9−36.5−49.7−38.6−31.1−33.0
Plus D&A2.817.328.738.444.247.0
Less capex−25.0−160.0−150.0−110.0−80.0−75.1
Less working capital−9.5−28.7−61.3−16.8−3.2−22.6
Unlevered FCF6.436.099.3130.1137.3136.5
Present value6.433.181.595.590.180.0

Source: Penmark Research model, Valuation. Unlevered FCF = EBIT less tax, plus D&A, less capex and working capital; excludes customer prepayments; stock compensation treated as cash; cost of equity 11.9%, terminal growth 3.0%.

Exhibit 64: DCF value is $31.05 at 11.9% and 3.0%; no cell in the grid reaches the $38.88 price
$36.12$36.55$37.03$37.58$38.22$33.10$33.36$33.65$33.97$34.33$30.71$30.87$31.05$31.23$31.44$28.79$28.89$28.99$29.10$29.21$27.21$27.27$27.32$27.38$27.44Terminal growth2.0%2.5%3.0%3.5%4.0%Cost of equity9.9%10.9%11.9%12.9%13.9%

Source: Penmark Research model, Scenarios (closed-form DCF grid, base case, $ a share).

Exhibit 65: Two methods agree within 10.0%: $31.05 against $27.93 a share
$mDCFP/E
EV, 30 Sep 20261,523.31,266.1
Plus Tongmei net cash947.6947.6
Less deposits, JV minorities−84.7−84.7
Tongmei equity value2,386.22,129.0
New investors’ claim−469.6−444.7
Existing Tongmei minorities−238.6−209.6
AXT share of Tongmei1,678.01,474.7
Plus parent net cash350.8350.8
AXT equity, 30 Sep 20262,028.81,825.5
Value per share ($)31.0527.93

Source: Penmark Research model, Valuation (equity bridge: AXT holds 87.55% of Tongmei equity after the new investors’ claim; 66.1m shares; equity rolled to 6 Nov at 1.011x). DCF primary; mid-cycle P/E of 15.57x cross-check.

Exhibit 66: Terminal value is 50.5% of the $1,523.3m enterprise value
$0m$500m$1000m$1500m$2000mPV of FCF, 4Q26E toFY36EPV of terminal valueDCF enterprisevalue+$754m+$770m$1523m

Source: Penmark Research model, Valuation (DCF at 30 Sep 2026); $m.

Method and why

A DCF fits because FY27E to FY28E earnings are far above mid-cycle. The cross-check applies a 15.57x through-cycle P/E (range 12.71x to 21.02x) to FY27E normalised NOPAT of $59.95m, plus $332.7m of above-mid-cycle profit. The 10.0% gap is under the 15% threshold.

PART 4 · THE NUMBERS · 15 VALUATION (2 OF 2)

The $33.33 target implies −14.3%, and only a lower cost of equity moves the rating

Exhibit 67: AXT trades at 14.8x FY27E earnings against a 16.5x peer median, with higher growth and margin
6 Nov 2026PriceFwd P/EBetaGross marginGrowth, 3YThrough-cycle P/E
Coherent$192.8016.5x2.2338.2%43.0%n/a
Lumentum$538.6018.5x1.6548.0%69.3%n/a
Photronics$27.3613.3x1.3233.7%3.7%12.7x
SUMCO*¥3,11772.4x1.129.3%10.4%21.0x
AXT, at price$38.8814.8x2.0144.0%101%n/a

Source: Penmark Research model, Peers (S&P Global Market Intelligence data, Signals, 6 Nov 2026; *SUMCO 25 Sep). Peer multiples at price; AXT non-GAAP FY27E EPS $2.63. AXT growth is the FY25A to FY28E revenue CAGR and gross margin is trailing twelve months (56.1% in 3Q26); Siltronic (15.6x through-cycle) sets the anchor only; Entegris and MACOM are excluded.

Exhibit 68: Probability-weighting gives a $33.33 target: −14.3% against $38.88, a Sell
CaseProbabilityValueTargetReturnRating
Bear30%$10.70$11.98−69.2%Sell
Base50%$31.05$34.74−10.6%Sell
Bull20%$55.27$61.85+59.1%Buy
Weighted100%$29.79$33.33−14.3%Sell

Source: Penmark Research model, Scenarios. Target = value x (1 + 11.9% cost of equity); no dividend. Probabilities are analyst judgements. Unrounded return −14.27%.

Exhibit 69: Reverse DCF: the $38.88 price needs a 53.8% margin, a 9.5% cost of equity or 9.6% terminal growth
One input solved at a timePenmarkPrice-implied
Mid-cycle gross margin40.0%53.8%
Cost of equity11.9%9.5%
Terminal growth3.0%9.6%

Source: Penmark Research model, Market Check (each solve changes one input, base case, to reach $38.88).

Exhibit 70: Only a 1pt lower cost of equity changes the rating, to Hold at −7.8%
Robustness testWeighted valueTargetReturnRating
Cost of equity −1pt$32.32$35.84−7.8%Hold
Cost of equity +1pt$27.79$31.37−19.3%Sell
Beta 1.41 (peers)$29.79$33.33−14.3%Sell
Beta 2.01 (AXT own)$24.81$28.51−26.7%Sell
Hist. margin, all$23.91$26.75−31.2%Sell

Source: Penmark Research model, Market Check (full model re-runs at the 6 Nov 2026 price and inputs).

Reconciliation to page 1

Target $33.33 = $29.79 x 1.119. Bear $10.70 (30%), base $31.05 (50%) and bull $55.27 (20%) tie to the values behind Exhibit 3 (targets $11.98, $34.74 and $61.85). At an unchanged $33.33 target, a Buy needs a price below $30.30 and the Sell is invalidated if the price falls below $37.04 (Hold between the two). At today’s price, a weighted value above $38.2 would be a Buy and one at or below $31.3 remains a Sell.

Limits

Probabilities rest on judgement; the bull case needs several things at once.

Exhibit 71: Only the bull value of $55.27 is above the $38.88 price; base, weighted value and target are all below it
Bear valueProbability-weighted valueBase valuePrice targetPrice, 6 Nov 2026Bull value$10.70$29.79$31.05$33.33$38.88$55.27

Source: Penmark Research model, Scenarios; values at 6 Nov 2026, target 12 months forward.

PART 4 · THE NUMBERS · 16 OWNERSHIP AND TRADING

Index funds and trading firms hold the stock, and short interest is up 59% since April

Exhibit 72: The ten largest filers held 27.1m shares, 41% of the stock, at 30 June 2026
BlackRockVanguardMarex GroupJane StreetD. E. ShawGeode CapitalT. Rowe PriceState StreetCitadel AdvisorsClear Street5.15.03.63.52.21.71.71.51.51.3

Source: SEC 13F filings via Signals, period 30 Jun 2026; 13F filers reported 45.9m shares, 70.0% of 65.6m outstanding. Shares in millions.

Exhibit 73: Short interest rose to 12.0m shares on 15 October, 18.3% of shares outstanding and 1.41 days of volume
0.02.55.07.510.012.530Apr15May29May15Jun30Jun15Jul31Jul14Aug31Aug15Sep30Sep15Oct7.58.37.37.611.311.010.110.89.28.810.812.0

Source: FINRA short interest via Signals, 30 Apr to 15 Oct 2026 (2026 settlement dates); percentage of 65.6m shares outstanding, Penmark Research calculation.

Exhibit 74: Street targets run from $56 to $125, all above the $38.88 price; our $33.33 target is the lowest
Penmark target $33Street low $56Street high $125Price, 6 Nov 2026 $39Street mean $94

Source: Third-party Street target data (low $56, mean $94.46, high $125; Street ratings 3 Buy, 2 Hold, 1 Sell); Penmark Research model. Street targets were set before the October to November sector sell-off.

Exhibit 75: Insiders sold $29.2m in June to August 2026 at $87 to $115; October filings are grants
InsiderDateTransactionSharesPrice
Morris S. Young, CEO1 to 2 Jun 2026Option exercises, sales197,498 sold$112 to $113
Jesse Chen, lead director3 to 15 Jun 2026Open-market salesAbout 55,000 sold$87 to $115
David C. Chang, director15 Jun 2026Sale8,333 sold$111.17
Leonard J. LeBlanc, director7 to 17 Aug 2026Sales6,000 sold$88 to $96
Morris S. Young, CEO27 Oct 2026Equity grant23,350 grantedn/a
Gary L. Fischer, CFO27 Oct 2026Equity grant8,524 grantedn/a

Source: SEC Form 4 filings via Signals, 1 Jun to 29 Oct 2026. Sales are selected filings; Form 4 data do not show why an insider sold.

Who owns it

Index funds and market makers are the largest filers. BlackRock (5.07m shares, $365.6m at 30 June) and Vanguard (5.00m, $360.3m) lead; Marex and Jane Street, both trading firms, follow. The 13F data cover only filers above the reporting threshold and say nothing about holders that are absent.

Trading and positioning

Short interest is up 59% since 30 April (7.55m to 11.98m shares) while the stock fell 54% in a month. Days to cover of 1.41 means shorts can exit within about a day and a half of average volume, so the position adds volatility rather than a squeeze risk.

PART 5 · APPENDIX · 17 FINANCIAL MODEL

The model takes revenue from $88.3m to $717.0m and EBITDA to $360.3m by FY28E

Exhibit 76: Annual model: EBITDA moves from −$12.9m in FY25A to $360.3m in FY28E on an 8.1x rise in revenue
$m unless statedFY24AFY25AFY26EFY27EFY28E
Revenue99.488.3237.9509.9717.0
Gross profit23.811.2128.5305.9401.5
EBITDA−5.8−12.991.7261.3360.3
EBIT−14.8−22.081.3243.9331.5
Net income to AXT−11.6−21.372.5169.2223.2
Diluted EPS, GAAP ($)−0.27−0.491.132.563.38
Operating cash flow−12.1−12.8n/a244.7264.3
Capital expenditure−5.8−6.0n/a−160.0−150.0
Free cash flow−17.9−18.8n/a84.7114.3
Cash and investments22.8128.41,383.81,468.51,582.8
Total equity (incl. minorities)254.9334.61,572.41,808.42,120.3

Source: Company 10-K filings via Signals (A); Penmark Research model, Financials (E). FY26E free cash flow not modelled because nine-month cash flow was not filed. Total assets at 30 Sep 2026 are model estimates; the 3Q26 10-Q was not filed at the model date.

Exhibit 77: Quarterly gross margin rose from 6.1% to 56.1% in seven quarters; we model 64.5% for 4Q26
$m1Q252Q253Q254Q251Q262Q263Q264Q26E
Revenue19.418.028.023.026.947.673.490.0
Gross margin, non-GAAP6.1%8.2%22.4%21.5%29.9%45.0%56.1%64.5%
Operating income, GAAP−10.3−6.7−1.1−3.8−1.610.428.444.1
Net income to AXT−8.8−7.0−1.9−3.5−1.611.125.737.3

Source: Signals quarterly statements (10-Q and 10-K) and company releases (A); Penmark Research model (E). Gross margin non-GAAP for actual quarters; model gross margin for 4Q26E.

Exhibit 78: Indium phosphide is 71% of FY26E revenue and 85% in FY27E
Revenue by product, $mFY25A3Q26AFY26EFY27EFY28E
Indium phosphiden/a54.3169.5433.2633.6
Gallium arseniden/a9.130.234.738.2
Germaniumn/a0.31.21.21.2
Substrates, total58.963.7200.8469.1673.0
Raw materials and other29.49.737.140.844.0
Total revenue88.373.4237.9509.9717.0

Source: Company 10-K FY25 (revenue by product type) and 3Q26 call, CFO remarks (A); Penmark Research model, Revenue build (E). Indium phosphide revenue is capacity x utilisation x price index; not split out in the FY25 10-K on this basis.

Exhibit 79: Backlog above $500m and a $90m 4Q26E revenue guide anchor the model
$500m+Backlog, 3Q26$90m4Q26E revenue guide50.2%FY28E EBITDA margin$1,383.8mFY26E cash and investments

Source: Company 3Q26 call; Penmark Research model, Financials. Balance-sheet figure is a model estimate.

PART 5 · APPENDIX · 18 REFERENCE

Reference: GAAP to non-GAAP, definitions, peer set and method

Exhibit 80: Non-GAAP EPS exceeds GAAP EPS by $0.07 in every forecast year; only stock compensation is added back
$ a shareFY25AFY26EFY27EFY28E
GAAP diluted EPS−0.491.132.563.38
Add back SBC0.070.070.070.07
Non-GAAP diluted EPS−0.421.202.633.45
SBC, $m3.34.04.54.8
Diluted shs, m43.962.866.166.1

Source: Company 10-K FY25 and 3Q26 release (A); Penmark Research model, Financials (E).

Exhibit 81: Non-GAAP EPS is $0.07 above GAAP in every forecast year
GAAP EPS, $Non-GAAP EPS, $−$1$0$1$2$3$4FY25AFY26EFY27EFY28EActualEstimates−$0.49−$0.42$1.13$1.20$2.56$2.63$3.38$3.45

Source: Company 10-K FY25 (A); Penmark Research model, Financials (E).

Glossary

InP indium phosphide, the substrate for lasers and detectors in optical links. GaAs gallium arsenide, used in wireless, LEDs and sensors. Ge germanium, used in solar cells and infrared optics. EPD etch pit density, a measure of crystal defects. VGF vertical gradient freeze crystal growth. Tongmei Beijing Tongmei Xtal Technology, AXT’s main operating subsidiary. LTA long-term agreement. Qualified IPO a listing that releases the 8% redemption floor for new Tongmei investors.

Ratio definitions

Price return is the 12-month target divided by the price, minus one, excluding dividends. Target is probability-weighted value x (1 + cost of equity). Cost of equity is 4.9% + 1.41 x 5.0% = 11.9%. FCF is operating cash flow less capex; the DCF uses FCF excluding customer prepayments and treats stock compensation as a cash cost.

Peer set

Coherent, Lumentum, Photronics and SUMCO set beta and forward P/E; Photronics, SUMCO and Siltronic set the 15.57x through-cycle P/E anchor. Entegris (acquisition amortisation) and MACOM (chip designer) are excluded from the anchor.

Methodology

Primary method is a DCF; the cross-check is a mid-cycle P/E. The archetype is volume x price for a capacity-constrained materials maker, so we show gross margin, utilisation and backlog rather than a regression of P/E on growth. Forward P/E bands are not meaningful because AXT lost money in FY23 to FY25; Exhibit 15 shows a gross-margin band instead. Catalysts and risks are carried in Exhibits 13 and 14 on page 4. Price-date balance-sheet items at 30 Sep 2026 are model estimates, customer deposits are estimated at $57.5m, the cash split uses the 30 June 2026 disclosure, and the Tongmei investor price is assumed equal to AXT’s.

Data sources

Model date and price date 6 Nov 2026. Company 10-K FY25, 10-Q 2Q26, 8-K 29 Oct 2026, proxy statement 2026 and call transcripts via Signals; Yahoo Finance prices and consensus (LSEG); S&P Global Market Intelligence peer data.

Exhibit 82: Four inputs set the valuation: 11.9% cost of equity, 3.0% growth, 15.57x, 40.0% margin
11.9%Cost of equity3.0%Terminal growth15.57xMid-cycle P/E anchor40.0%Mid-cycle gross margin

Source: Penmark Research model, Methodology and Valuation.

PART 5 · APPENDIX · 19 DISCLOSURES

Analyst certification and important disclosures

Ratings

Ratings are based on the upside from the share price to our 12-month price target, excluding dividends. The price target is weighted across bull, base and bear scenarios.

BuyUpside to price target above +10%
HoldUpside to price target from −10% to +10%, inclusive
SellUpside to price target below −10%

We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.

Analyst certification

The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.

Contact

Penmark Research

Questions about our research:
research@penmarkresearch.com

All our research and coverage:
penmarkresearch.com

Basis of preparation

This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.

Valuation and price targets

Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.

Independence and conflicts of interest

Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.

No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.

Regulatory status

Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.

Not investment advice or an offer

This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.

Forward-looking statements and risk

Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.

Data and sources

Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.

Accuracy and liability

Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.

Distribution and access

Penmark Research reports are available through penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research terms of use. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.

Copyright and permitted use

© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.

Keep reading

Sign in to Penmark